Home
Categories
Ingredients
Research & Development
Manufacturing
Packaging
Active Nutrition
Cardiovascular
Digestion
Cognitive
Finance
Regulatory
Company News
Events
Directory
Search
Close search
Home
Company
GW Pharmaceuticals
GW Pharmaceuticals
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
DolCas Biotech exhibits novel curcumin chocolate at Vitafoods Europe
Curcugen, the curcumin-infused dark chocolate, can offer support in gut health and mood management
ADM exceeds 2m acre regenerative agriculture goal for 2023
Launch of regenerative agriculture initiatives in Europe, Latin America accelerate global progress as company works toward 3.5 million acres in 2024
Epax slashes carbon emissions in its transition to renewables
The company is now powered by 100% renewable energy and has reduced its emissions by 22.3% in the last 4 years
Sygnature Discovery receives Ecovadis award for sustainable excellence
The award recognises the company's efforts to enhance its social and ethical performance with high standards
Sirio launch PureOrganix range of gummies and softgels at Vitafoods Europe
The new market-ready organic range includes top-trending ingredients, including EPO, flaxseed oil and apple cider vinegar
Upcoming event
Vitafoods Europe
14–16 May 2024 | Exhibition | Palexpo, Geneva
See all
Related Content
Finance
GW Pharmaceuticals reports Epidiolex sales of $296 million in first year
The British biopharmaceutical company has released Q4 and 2019 financial year results
Manufacturing
Momentum in the US cannabidiol market gains retailers' attention
Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Regulatory
First prescription CBD from GW Pharma has restriction lowered
The US Drug Enforcement Administration’s decision to move Epidiolex to Schedule V was based on non-clinical and clinical data that evaluated the medicine’s potential for abuse
Ingredients
Marijuana derivative reduces seizures in children and young adults with treatment-resistant epilepsy
New open-label trial of prescription cannabidiol shows overall safety and efficacy
Subscribe now